ClinicalTrials.gg
Not yet recruitingNCT07856043NEURO-HFUpdated Nov 17, 2026

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction

A Phase 1 interventional study of [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand and Sacubitril-Valsartan in Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild and Neuroinflammation, sponsored by Stony Brook University. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Stony Brook University · Phase 1, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,423 studies in Cognitive Dysfunction with a site in United States — 330 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
947th of 1,147
18 · median 59
Started
2027
with 8 others
Phase 1
102 of 1,423
20 open now
Primary completion
2028-06
later than 329 of 431 live
Registered
1,417th of 1,423
by date

Among the 1,423 studies in Cognitive Dysfunction with a site in United States, this one is the 947th largest by planned enrollment of the 1,147 interventional ones that give a count, is one of 9 that started in 2027, is one of 102 in phase 1, reaches primary completion later than 329 of the 431 other live ones, and was the 1,417th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

330 of the 1,423 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

325 more — sign in →

All 330 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,423 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain immune cells (called microglia) become overactive. A heart failure medication called sacubitril-valsartan has been shown to reduce the risk of developing dementia, but it is not known whether this is because it reduces brain inflammation. This study uses a new experimental brain scan drug called [11C]PS13 (PS13) to measure brain inflammation directly and non-invasively, using a technique called positron emission tomography (PET). PS13 sticks to a molecule called COX-1, which is found mainly in brain immune cells (microglia). By measuring how much PS13 accumulates in the brain, researchers can estimate how much brain inflammation is present. In this pilot study, 18 patients with heart failure and mild memory or thinking problems who are being started on sacubitril-valsartan by their cardiologist (as standard clinical care) will undergo two brain PET scans: one before starting sacubitril-valsartan, and one approximately 12 weeks after. The study will also assess memory, thinking, daily function, mood, and social well-being using standard questionnaires. The study will test whether sacubitril-valsartan is associated with measurable changes in brain inflammation, and whether this type of imaging is feasible in heart failure patients. The study is funded by the American Heart Association and the National Institute on Aging, and an independent Data and Safety Monitoring Board oversees participant safety. The results will be used to design a larger study.

Read the detailed description

Heart failure with reduced ejection fraction (HFrEF) affects \~6.7 million Americans and is a powerful independent risk factor for accelerated cognitive decline and dementia, playing a major role in vascular contributions to cognitive impairment and dementia (VCID). Neuroinflammation, and particularly microglial activation, is a leading mechanistic hypothesis for HFrEF-associated cognitive decline, driven by chronic cerebral hypoperfusion and systemic inflammatory signaling. However, direct in vivo evidence of neuroinflammation in living HFrEF patients is lacking. Sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor [ARNI]) is guideline-directed first-line therapy for HFrEF. Beyond established cardiovascular benefits, epidemiological data demonstrate a >30% reduction in incident dementia and cognitive decline with sacubitril-valsartan vs. standard renin-angiotensin inhibitors over 3 years, suggesting neuroprotective properties. These may be mechanistically linked to anti-inflammatory actions via natriuretic peptide signaling and neprilysin-mediated peptide degradation, a hypothesis that has not yet ben=en testedhas not yet been tested in the living human brain. [11C]PS13 is a novel PET radioligand developed at Stony Brook University targeting cyclooxygenase-1 (COX-1), a microglial-specific marker of neuroinflammatory activity.is a novel PET radioligand, co-developed by study co-investigator Dr. Min-Jeong Kim, that selectively targets cyclooxygenase-1 (COX-1), which is primarily localized in microglia and serves as a biomarker of microglial density and neuroinflammatory activity. [11C]PS13 has demonstrated excellent selectivity and signal-to-noise in non-human primates and healthy humans (Kim et al., J Nucl Med 2018; Kim et al., Eur J Nucl Med Mol Imaging 2020), and elevated binding in Alzheimer's disease and dementia with Lewy bodies compared to controls.and increased binding in Alzheimer's disease compared with age-matched healthy controls; work in dementia with Lewy bodies is ongoing. The present study extends [11C]PS13 PET to patients with HFrEF to: (1) establish feasibility of this neuroimaging approach in a cardiac population; (2) characterize baseline brain microglial density (COX-1 expression) in HFrEF patients with mild cognitive impairment; and (3) generate preliminary effect size data for changes in neuroinflammation after sacubitril-valsartan initiation. In addition to PET imaging, participants will undergo a comprehensive neurocognitive assessment at baseline and follow-up, including evaluation of global cognition, processing speed, executive function, free recall, depression, loneliness, social isolation, social network, and instrumental activities of daily living. This AHA-funded pilot will provide the foundational data for a more definitive mechanistic study.The study will enroll 18 participants under a single protocol (6 supported by the American Heart Association and 12 by the National Institute on Aging, R21AG102953), with data pooled for analysis. [11C]PS13 is administered under FDA IND 177118, and an independent, NIA-appointed Data and Safety Monitoring Board oversees participant safety, data quality, and study progress. This pilot will provide the foundational data for a more definitive mechanistic study.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • Cognitive Impairment, Mild
  • Neuroinflammation
  • Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Keywords

  • [11C]PS13
  • PET neuroimaging
  • Cyclooxygenase-1 (COX-1)
  • Microglia
  • Sacubitril-valsartan
  • ARNI
  • Heart failure
  • Brain inflammation
  • Cognitive decline
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-75 years
  • Diagnosis of HFrEF ( ≤40% documented by echocardiography or cardiac imaging within the prior 12 months)
  • (MoCA) score 18-25 (mild cognitive impairment)
  • Being initiated on sacubitril-valsartan per treating cardiologist's clinical judgment in accordance with current guideline-directed medical therapy for HFrEF
  • Clinically stable HF ( functional Class I-III) at time of enrollment
  • Ability to provide written
  • Ability to lie flat for up to 90 minutes (required for PET scan acquisition)

Exclusion criteria

Exclusion Criteria:

  • Neurologic, psychiatric, or medical condition that may cause cognitive dysfunction or affect study data interpretation (e.g., major stroke, brain tumor, severe TBI, epilepsy, multiple sclerosis, schizophrenia, bipolar disorder)
  • Clinically unstable HF or acute decompensated heart failure within 4 weeks prior to enrollment
  • functional Class IV heart failure
  • Recent hospitalization for cardiovascular reasons within 4 weeks of enrollment
  • Severe pulmonary congestion or orthopnea precluding lying flat for \~90 minutes
  • Recent cardiac surgery within 3 months of enrollment
  • Implanted cardiac device (e.g., pacemaker, ICD, CRT-D) that is non-MRI-conditional, in the absence of an available clinical brain MRI from within the past 3 years
  • Other implanted device for MRI (e.g., deep brain stimulator, cochlear implant, intracranial aneurysm clip)
  • Current drug or alcohol abuse or dependence
  • Recent research radiation exposure that combined with this study would exceed allowable limits as determined by the FDA
  • Inability to remain still on the scanner bed or body weight exceeding scanner maximum
  • Use of NSAIDs other than low-dose aspirin (≤100 mg/day) within 2 weeks prior to each [11C]PS13 PET scan
  • Pregnancy or breastfeeding
  • Severe renal impairment ( \<30 mL/min/1.73m²) or other condition that may affect radioligand clearance or biomarker interpretation
  • Active systemic inflammatory or disease
  • Peripheral vascular disease or other condition precluding radial arterial catheter placement
  • Anticoagulation at therapeutic levels that would substantially increase the risk of arterial line placement (e.g., warfarin with >3.0, therapeutic heparin); patients on direct oral anticoagulants (DOACs) are assessed individually by the study physician
  • Whole blood or plasma donation within 8 weeks (56 days) before the first PET scan, or unwillingness to refrain from blood donation for the duration of study participation
  • Non-English speaking (the and the consent process require English-language comprehension)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    HFrEF with Mild Cognitive Impairment - Sacubitril-Valsartan Initiators

    Patients with HFrEF (LVEF ≤40%) and mild cognitive impairment (MoCA 18-25) who are being initiated on sacubitril-valsartan per their cardiologist's clinical judgment. Participants undergo \[11C\]PS13 PET brain imaging with arterial blood sampling and brain MRI at baseline (prior to sacubitril-valsartan initiation) and at approximately 12 weeks after initiation.

    Drug: [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand · Drug: Sacubitril-Valsartan

Interventions

  • Drug[11C]PS13: [carbon-11]PS13; COX-1 PET radioligand

    \[11C\]PS13 is an investigational positron emission tomography (PET) radioligand targeting cyclooxygenase-1 (COX-1), an enzyme primarily localized in microglia involved in neuroinflammation. Synthesized on the day of each scan at the Stony Brook BAHL cGMP or FERM facility, administered as a single intravenous bolus (up to 20 mCi) per PET visit. Administered under FDA IND 177118 (21 CFR Part 312). Not FDA-approved; experimental.

  • DrugSacubitril-Valsartan

    Angiotensin receptor-neprilysin inhibitor (ARNI) initiated by the participant's treating cardiologist per ACC/AHA/HFSA guideline-directed medical therapy for HFrEF. The dose, titration, and monitoring of sacubitril-valsartan are entirely at the discretion of the treating cardiologist and are not research procedures. The timing of the follow-up PET scan (\~12 weeks post-initiation) is aligned with expected clinical stabilization on the drug.

06

What researchers measure

Primary outcomes

  1. Change in [11C]PS13 Total Distribution Volume (VT) in Global Gray Matter

    Change in regional \[11C\]PS13 total distribution volume (VT, mL/cm³), a quantitative index of COX-1 binding (microglial density), in global cortical gray matter. VT will be calculated using two-tissue compartmental modeling with an arterial blood input function (arterial plasma concentration corrected for radiometabolites). A reduction in VT at follow-up relative to baseline is hypothesized to reflect sacubitril-valsartan-mediated attenuation of microglial neuroinflammation.

    Time frame: Baseline (Visit 2, prior to sacubitril-valsartan initiation) and approximately 12 weeks after initiation (Visit 4)

Secondary outcomes

  1. Feasibility: [11C]PS13 PET Scan Completion Rate

    Proportion of enrolled participants who successfully complete both PET scan visits with adequate image quality for quantitative analysis. Arterial line success rate and reasons for scan non-completion will be documented. A completion rate of ≥80% will be considered evidence of feasibility in this cardiac population.

    Time frame: Through study completion, approximately 16 weeks per participant

  2. Change in Regional [11C]PS13 VT in Specific Brain Regions of Interest

    Change in \[11C\]PS13 VT in pre-specified regions of interest including frontal cortex, temporal cortex, hippocampus, parietal cortex, occipital cortex, cingulate cortex, and thalamus, evaluated using PET-MRI co-registration and Logan graphical analysis. Regional analysis will explore the spatial pattern of neuroinflammation in HFrEF and its response to sacubitril-valsartan.

    Time frame: Baseline (Visit 2) and ~12 weeks (Visit 4)

  3. Change in Neurocognitive Performance (Composite Battery)

    Change in performance on the standardized neurocognitive battery instruments administered at both baseline (Visit 1) and follow-up (Visit 4): Montreal Cognitive Assessment (MoCA; global cognition), Digit Symbol Substitution Test (DSST; processing speed), Trail Making Test Parts A and B (TMT-A/B; processing speed and executive function), Free and Cued Selective Reminding Test immediate and delayed recall (FCSRT; episodic memory), and Geriatric Depression Scale-15 item version (GDS-15; depression symptoms). The battery takes approximately 45-60 minutes to administer. Spearman correlations between ΔVTPET and changes in individual test scores will be explored as exploratory analyses.

    Time frame: Baseline (Visit 1) and ~12 weeks (Visit 4)

  4. Arterial Blood Input Function Quality and Radiometabolite Profile

    Characterization of the \[11C\]PS13 arterial plasma input function and radiometabolite-corrected curves in HFrEF patients at both time points. This will inform whether the pharmacokinetic profile of \[11C\]PS13 in HFrEF patients is comparable to prior neurological cohorts, a key methodological feasibility outcome.

    Time frame: Baseline (Visit 2) and ~12 weeks (Visit 4)

  5. Change in Instrumental Activities of Daily Living (IADL / Lawton-Brody Scale)

    Characterization of the \[11C\]PS13 arterial plasma input function and radiometabolite-corrected curves in HFrEF patients at both time points. This will inform whether the pharmacokinetic profile of \[11C\]PS13 in HFrEF patients is comparable to prior neurological cohorts, a key methodological feasibility outcome.

    Time frame: Baseline (Visit 2) and ~12 weeks (Visit 4)

07

Study locations

1 site
08

References and documents

Publications

  • Ghazanfari N, Liow JS, Kim MJ, Cureton R, Lee A, Knoer C, Jenkins M, Hong J, Santamaria JAM, Shetty HU, Galassi A, Wighton P, Norgaard M, Greve DN, Zoghbi SS, Pike VW, Innis RB, Zanotti-Fregonara P. [11C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain. J Nucl Med. 2025 Jan 3;66(1):117-122. doi: 10.2967/jnumed.124.267928. PubMed 39542698 ↗
  • Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, Singh P, Cortes MY, Henry K, Tye GL, Frankland MP, Montero Santamaria JA, Liow JS, Zoghbi SS, Fujita M, Pike VW, Innis RB. First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3143-3151. doi: 10.1007/s00259-020-04855-2. Epub 2020 May 12. PubMed 32399622 ↗
  • Grewal PK, Abboud A, Myserlis EP, Goldschmidt ME, Butler J, Skopicki HA, Kalogeropoulos AP. Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Adv. 2023 Jun 7;2(4):100372. doi: 10.1016/j.jacadv.2023.100372. eCollection 2023 Jun. PubMed 38938237 ↗

Individual participant data

Plan to share: Yes — De-identified participant-level brain PET imaging data ([11C]PS13), structural MRI data (MP-RAGE, T2-FLAIR), cognitive assessment scores (MoCA, DSST, TMT-A/B, FCSRT), and associated clinical metadata (demographics, HF characteristics, NT-proBNP) will be shared. Data will be formatted in Brain Imaging Data Structure (BIDS) standard per Knudsen et al. (J Cereb Blood Flow Metab 2020). Plasma biospecimens will be transferred to NCRAD after 5 years. Analytic code and the statistical analysis plan will also be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: De-identified imaging data, cognitive scores, and clinical metadata will be made available no later than the time of the primary associated publication, or at the end of the study performance period, whichever comes first. Supporting documents (SAP, ICF, analytic code) will be shared simultaneously. All shared data will remain available indefinitely with no end date.

Access criteria: Qualified researchers may request access to de-identified brain PET and MRI images, cognitive assessment scores, and clinical metadata via OpenNeuro PET Archive (openneuro.org). Access is initially granted through the repository review process. After an optional 36-month grace period from initial deposit, data will be released under a Creative Commons CC0 license for unrestricted reuse. Facial features will be removed from structural MRI prior to upload.

Data sharing details ↗ · openneuro.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2028, 17 months later.

Of 54 non-industry phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 17 months is below that.

Counting every sponsor, half of 80 studies reached it within 29 months; a quarter within 13 and three quarters within 49.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Nov 17, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 17, 2026
    Start date Oct 1, 2026→Jan 1, 2027
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856043
Collaborators
American Heart Association, National Institute on Aging (NIA)
Responsible party
Andreas Kalogeropoulos (Director, Cardiovascualr Research, Stony Brook University) — Principal investigator
First posted
Oct 2, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Andreas Kalogeropoulos, MD MPH PhD
Contact
Andreas.Kalogeropoulos@stonybrookmedicine.edu
404-512-4463
Min-Jeong Kim, MD PhD
Contact
MinJeong.Kim@stonybrookmedicine.edu
631-638-3154

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion